No, science hasn't established that CBD helps you sleep. What it has established is more nuanced: an old case series reported improved sleep in some patients, but fragile over time; more recent, better-designed controlled trials mostly find no clear difference from placebo on objective measures of insomnia.
That doesn't mean nothing happens when you use a flower or resin in the evening. It means that what happens isn't demonstrated as a specific effect of CBD on sleep, in the sense clinical research gives that term.
This guide sums up the studies that actually matter, without drawing from them a promise that a French seller isn't allowed to make anyway.
Key points — The most cited study (Shannon 2019) is a case series with no placebo: sleep improved in 67% of patients in the first month, then that result fluctuated. More recent controlled trials (Narayan 2024, on primary insomnia) show no clear difference from placebo on most sleep measures. A 2020 review (Suraev) points to the glaring lack of randomized trials on clinically diagnosed insomnia. CBN, often presented as the sleep cannabinoid, also lacks solid evidence according to a 2021 review. The treatment with demonstrated efficacy remains cognitive behavioral therapy for insomnia (CBT-I).
What the 2019 Shannon study actually showed
It's the reference you'll run into everywhere: Shannon et al., Cannabidiol in Anxiety and Sleep: A Large Case Series, published in The Permanente Journal in 2019. It's a retrospective case series conducted at a US psychiatric clinic, involving 72 adults who came in for anxiety or sleep problems, alongside their usual care.
Among patients followed for sleep, the score improved in about two-thirds of them during the first month — but that result fluctuated over the course of follow-up, unlike the anxiety scores, which stayed stable for the duration of the study. That's an important nuance that a lot of marketing content leaves out.
A case series has no placebo group, no randomization, no double-blinding: it documents what happened in patients under observation, without letting you know what would have changed without CBD, or ruling out the effect of the clinical context, expectation, or the rest of the therapeutic follow-up. It's a starting point for research, not a conclusion.
More recent controlled trials: results that are far from clear-cut
Since then, better-designed trials have tested CBD directly on insomnia. A randomized pilot trial published in 2024 (Narayan et al., in Psychopharmacology then Journal of Clinical Sleep Medicine) compared 150 mg of sublingual CBD to a placebo, in adults with moderate to severe primary insomnia, over two weeks.
Result: insomnia severity, reported time to fall asleep, and nighttime wake time did not differ between the two groups. The CBD group reported a more pronounced subjective sense of well-being and a slightly higher sleep efficiency after two weeks, measured by actigraphy — but on most insomnia criteria, there was no significant difference from placebo.
This is an honest result worth knowing: CBD can influence a general sense of well-being without that translating into a measurable improvement in insomnia itself. That's very different from "it works against insomnia."
The 2020 Suraev review's finding: little solid data
A systematic review published in Sleep Medicine Reviews in 2020 (Suraev et al.) surveyed the preclinical and clinical literature on cannabinoids and sleep. Its central conclusion: very few randomized controlled trials focus specifically on clinician-diagnosed insomnia, and the available data don't allow a firm conclusion about CBD's effectiveness in this context.
This isn't a review that says "it doesn't work." It's a review that says "we don't know yet," which is very different from the headlines you sometimes read online.
Why expectation and ritual count as much as the molecule
In every placebo-controlled trial, the control group improves too — that's the placebo effect, a real and documented phenomenon, particularly strong on subjective measures like perceived sleep. Part of what gets attributed to CBD probably comes from what surrounds it:
- The ritual itself: stopping, preparing something, switching off screens a few minutes before bed.
- The expectation of an effect: knowing you took something "for sleep" already changes how you perceive your own ability to fall asleep.
- The context of use: a quiet room, a regular routine, no stimulation right before bed.
None of that is specific to CBD. It's true of pretty much anything you turn into an evening ritual.
CBN: the reputation far outpaces the evidence
CBN (cannabinol) is often presented as "the sleep cannabinoid." A review published in 2021 in Cannabis and Cannabinoid Research (Corroon) looked specifically at this question: out of 99 human studies screened, only eight met the inclusion criteria, most dating from the 1970s-1980s, with small, unrepresentative samples. The author's conclusion: the published evidence is insufficient to support the sleep claims attached to CBN.
Since then, a few more recent and better-designed trials have been published — including a 2023 controlled trial on CBN alone and combined with CBD, and a 2024 trial comparing several CBN quantities to melatonin. The results are encouraging but still few in number, with small samples; it's not yet the level of evidence that would allow a general conclusion. If you want to dig into CBD:CBN combinations sold as a "sleep ratio," the full breakdown is here — and the short answer is that no commercial ratio is validated by a study.
What's actually demonstrated against chronic insomnia
This is the point CBD product pages almost always leave out: there is a treatment with well-established efficacy against chronic insomnia, and it isn't a molecule — it's a method. Cognitive behavioral therapy for insomnia (CBT-I) is recommended as first-line treatment by the Haute Autorité de Santé (the French health authority) and by nearly every sleep medicine society worldwide. It combines time-in-bed restriction, stimulus control, restructuring of sleep-related thoughts, and relaxation techniques, with clinically significant results in most of the patients followed.
That's not incompatible with an evening ritual that includes a CBD flower or resin for the pleasure of the moment. It's just that if sleep is really a problem, this is the path with the strongest level of evidence — not a product page.
Smoking at night: a point worth naming
Many evening rituals involve combustion — a joint, a pipe, vaporizing a flower. Combustion remains harmful to the airways, whatever plant is being smoked, CBD included. If the evening gesture matters to you, vaporizing limits exposure to some combustion compounds compared with direct smoke, without eliminating it. See also our CBD vape guide to compare the options.
When to see a doctor instead of waiting on a product effect
Certain signs should point you toward a doctor rather than a shop:
- Sleep difficulties that have lasted more than three weeks and affect your day.
- Noticeable snoring with breathing pauses observed by people around you.
- Restless legs or unpleasant sensations that keep you from falling asleep.
- Anxiety or low mood accompanying the sleep problems.
A general practitioner can refer you to CBT-I, rule out an organic cause (sleep apnea, restless legs syndrome), or adjust an ongoing treatment.
What we can tell you, and what we can't
WorldWeed sells CBD flowers, resins and pre-rolls, not a sleep treatment. We can tell you what research shows, with its limits. We can't tell you that Tyson or Purple Haze will help you sleep: that would be a health claim, prohibited for a seller in France. CBD is not recommended for minors, pregnant or breastfeeding women, and medical advice is needed if you're on medication — see the details on side effects and safety. On the legal framework, see the full rundown on CBD in France.
Sources
- Shannon S., Lewis N., Lee H., Hughes S., « Cannabidiol in Anxiety and Sleep: A Large Case Series », The Permanente Journal, 2019.
- Narayan A.J. et al., « The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial », Psychopharmacology / Journal of Clinical Sleep Medicine, 2024.
- Suraev A.S. et al., « Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies », Sleep Medicine Reviews, 2020.
- Corroon J., « Cannabinol and Sleep: Separating Fact from Fiction », Cannabis and Cannabinoid Research, 2021.
- Haute Autorité de Santé, recommandations sur la prise en charge non médicamenteuse de l'insomnie chronique (thérapie cognitivo-comportementale de l'insomnie).
